Vanessa, a travel nurse from Memphis, Tennessee, had her life meticulously planned. She was building her career and saving for a home when a stage 3 triple-negative breast cancer diagnosis derailed everything. The most aggressive subtype of breast cancer, triple-negative, forced her to halt her ambitions and focus solely on treatment.
Even with her medical background, Vanessa found herself in unfamiliar territory. “I’ve taken care of patients my whole life,” she says, “but I didn’t really know what breast cancer truly entailed.” The initial treatment was swift, but the relief was short-lived. The cancer spread, and Vanessa was diagnosed with metastatic triple-negative breast cancer. “When I found out I had metastatic breast cancer, it was just an awful feeling to know you have to go through treatment again,” she recalls.
Triple-negative breast cancer is particularly aggressive, growing and spreading faster than many other types. For about half of women with metastatic triple-negative breast cancer, the first treatment may be the only chance to control the disease, making the initial choice critical. This subtype also disproportionately affects younger women, and Black and Hispanic women are more likely to develop it than other subtypes. For these communities, access to the latest education is not just helpful; it’s a matter of survival.
Historically, treatment options for metastatic triple-negative breast cancer were limited to chemotherapy, which affects all rapidly dividing cells. However, a newer class of medicines called antibody-drug conjugates (ADCs) offers a more targeted approach. ADCs are designed to bind to specific markers on cancer cells and deliver chemotherapy directly to them, potentially sparing healthy cells. Until recently, ADCs were reserved for later lines of therapy, but now they may be used as the first treatment after a metastatic diagnosis.
Innovations like ADCs have already made a difference for many patients by helping to keep cancer from growing. For Vanessa, this means better planning, knowing that she can schedule trips and family time around her treatment. However, not all ADCs are the same; safety and efficacy vary, and not every patient is eligible. Understanding when ADCs might be considered and how they affect daily life can empower patients to have informed discussions with their care team.
Dr. Gregory Vidal, MD, PhD, Director of Clinical Research at West Cancer Center and Associate Professor at the University of Tennessee Health Science Center, emphasizes the importance of individualizing treatment. “When selecting treatment, it’s important to consider patients’ goals, wishes and needs so that we can try to realistically plan around those,” he says. “All patients are different and may qualify for different ADCs.” He encourages patients to ask questions about treatment goals and to feel empowered in their care decisions.
For many living with metastatic breast cancer, treatment continues for life, aiming to manage the disease and maintain quality of life. Vanessa leaned on her support system to maintain “faith over fear,” focusing on positives and planning outings around her treatments. She advises others to stay positive, ask questions, and advocate for themselves. “You definitely have a fight in front of you, but you can get through this,” she says. “You have to do your research and get answers.”
To see how Vanessa and others navigate ADC treatment for metastatic triple-negative breast cancer, visit Expose-MBC.com/ADC.
